Adverse effects


Last updated: 2021 Jun 14
Total hit(s): 28
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
Among all treatment group patients, Lopinavir/ritonavir group patients experienced more serious adverse effects (52.8% in the lopinavir/ritonavir group vs. 38.5% in the control group; 54.2% in the lopinavir/ritonavir plus IFN-Ŗ-1a group vs. 38.5% in the control group). 44.1% of patients in the Hydroxychloroquine treated group had Serious adverse effects. 4 non-pulmonary-related deaths were found in two treatment groups (lopinavir/ritonavir group, n=1; lopinavir/ritonavir plus IFN-Ŗ-1a group, n=3).
Pre-print (medRXiv)
Date of Publishing -
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name -
Date of Entry 2021 Jun 14


The case study is of a 66-year-old man who experienced acute colic perforation after being treated with tocilizumab and corticosteroids for his COVID-19 diagnosis. The patient had a medical history of metabolic syndrome without any regular treatment.
32402416
(Cir Esp)
PMID
32402416
Date of Publishing: 2021 Feb
Title Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case
Author(s) nameGonz√°lvez Guardiola P, D√≠ez Ares J√Ā et al.
Journal Cir Esp
Impact factor
0.36
Citation count: 1


Compared to the placebo group patients, the fluvoxamine-treated group patients showed less serious adverse effects.
33180097
(JAMA)
PMID
33180097
Date of Publishing: 2020 Dec 8
Title Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
Author(s) nameLenze EJ, Mattar C et al.
Journal JAMA
Impact factor
14.78
Citation count: 6


Several common serious adverse effects were observed between two groups of patients (IFX-1 and control). In the IFX-1 group, 23 serious adverse effects occurred in 9 out of 15 patients. In the control group, 19 adverse effects occurred in 7 out of 15 patients.
33015643
(Lancet Rheumatol)
PMID
33015643
Date of Publishing: 2020 Dec
Title Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Author(s) nameVlaar APJ, de Bruin S et al.
Journal Lancet Rheumatol
Impact factor
<3years
Citation count: 8


A significant increase in Aminotransferase levels was observed in patients treated with Tocilizumab (TCZ), compared to Anakinra (ANA) treated group patients. Anakinra can be used to treat COVID-19 patients elevated aminotransferases and also useful for patients who do not respond to TCZ.
32843231
(J Autoimmun)
PMID
32843231
Date of Publishing: 2020 Dec
Title High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Author(s) nameIglesias-Julián E, López-Veloso M et al.
Journal J Autoimmun
Impact factor
7.32
Citation count: 3


Adverse effects were similar between two groups (Remdesivir and placebo) of patients. Serious adverse effects were reported in 131 patients in the Remdesivir group and 163 patients in the placebo group.
32445440
(N Engl J Med)
PMID
32445440
Date of Publishing: 2020 Nov 5
Title Remdesivir for the Treatment of Covid-19 Final Report
Author(s) nameBeigel JH, Tomashek KM et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 690


The patient treated with Remedesivir experienced acute liver failure which improved with the treatment of acetylcysteine The patient had a medical history of hypertension, diabetes mellitus, and hyperlipidemia.
33006138
(Pharmacotherapy)
PMID
33006138
Date of Publishing: 2020 Nov
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) name Carothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor
3.17
Citation count: 1


The patient treated with Remedesivir experienced acute liver failure which improved with the treatment of acetylcysteine The patient had a medical history of hypertension, diabetes mellitus, hyperlipidemia, and coronary artery disease (CAD)
33006138
(Pharmacotherapy)
PMID
33006138
Date of Publishing: 2020 Nov
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) name Carothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor
3.17
Citation count: 1


Adverse effects were common between treatment groups (hydroxychloroquine and control group). The most common adverse effects were gastrointestinal discomfort, diarrhea, headache, nausea, or dizziness. Few serious adverse events were also reported.
33082342
(Nat Commun)
PMID
33082342
Date of Publishing: 2020 Oct 20
Title A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics
Author(s) nameLyngbakken MN, Berdal JE et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 4


Patients with adverse effects were more in the HCQ group than the placebo group. The most common adverse effects were stomach upset, nausea, abdominal pain, diarrhea, or vomiting. No serious adverse effects were reported.
32673060
(Ann Intern Med)
PMID
32673060
Date of Publishing: 2020 Oct 20
Title Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 A Randomized Trial
Author(s) nameSkipper CP, Pastick KA et al.
Journal Ann Intern Med
Impact factor
11.75
Citation count: 83


Out of 25 patients treated with Tocilizumab, 23 experienced at least one adverse event. Anemia, alanine aminotransferase (ALT) rise, and QT interval prolongation were the most frequent adverse events. The median age of patients was 58 years (interquartile range, 50-63). Co-morbidities included diabetes mellitus, chronic kidney diseases, and cardiovascular disease.
32369191
(J Med Virol)
PMID
32369191
Date of Publishing: 2020 Oct
Title Tocilizumab for the treatment of severe coronavirus disease 2019
Author(s) nameAlattar R, Ibrahim TBH et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 58


This observational study is based on an algorithm that was structured to use tocilizumab for the treatment of COVID-19 patients with Cytokine Release Syndrome. Following tocilizumab treatment, oxygenation and inflammatory biomarkers improved. And D-dimer and soluble IL-2 receptor levels increased significantly.
32553536
(Chest)
PMID
32553536
Date of Publishing: 2020 Oct
Title Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
Author(s) namePrice CC, Altice FL et al.
Journal Chest
Impact factor
7.22
Citation count: 41


3 out of 4 patients, was observed to have serious adverse events. Patient 3 died due to multiple organ failures
32418190
(Infection)
PMID
32418190
Date of Publishing: 2020 Oct
Title Early experience with remdesivir in SARS-CoV-2 pneumonia
Author(s) nameDurante-Mangoni E, Andini R et al.
Journal Infection
Impact factor
2.84
Citation count: 5


4 Out of 5 patients treated with Remdesivir showed side effects. Age of case 1: 31-year-old. Age of case 2: 80-year-old Age of case 3: 39-year-old Age of case 4: 76-year-old Age of case 5: 70-year-old
32619764
(Int J Infect Dis)
PMID
32619764
Date of Publishing: 2020 Sep
Title Case report study of the first five COVID-19 patients treated with remdesivir in France
Author(s) nameDubert M, Visseaux B et al.
Journal Int J Infect Dis
Impact factor
3.42
Citation count: 6


Side effects were more common in patients treated with hydroxychloroquine than with placebo. The most common side effects were nausea, loose stools, and abdominal discomfort.
32492293
(N Engl J Med)
PMID
32492293
Date of Publishing: 2020 Aug 6
Title A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Author(s) nameBoulware DR, Pullen MF et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 268


Of 52 convalescent plasma-treated patients, 2 experienced adverse effects within an hour of transfusion. The observed adverse effects were Chills, rashes, shortness of breath, cyanosis, and severe dyspnea.
32492084
(JAMA)
PMID
32492084
Date of Publishing: 2020 Aug 4
Title Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
Author(s) nameLi L, Zhang W et al.
Journal JAMA
Impact factor
14.78
Citation count: 197


In this multi-center observational study, severe COVID-19 patients were treated with hyperimmune plasma therapy to reduce mortality. After transfusions, five serious adverse events occurred in four patients.
33256382
(Haematologica)
PMID
33256382
Date of Publishing: 2020 Jul 23
Title Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial
Author(s) namePerotti C, Baldanti F et al.
Journal Haematologica
Impact factor
7.53
Citation count: 26


The group of patients treated with only HCQ or HCQ + Azithromycin showed more serious adverse events (like Cardiac arrest, arrhythmia, and QT prolongation) compared to patients who did not receive any drug.
32392282
(JAMA)
PMID
32392282
Date of Publishing: 2020 Jun 23
Title Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Author(s) nameRosenberg ES, Dufort EM et al.
Journal JAMA
Impact factor
14.78
Citation count: 313


This study compares the effect of convalescent plasma therapy against the control group on viral shedding and survival in COVID-19 patients with serious respiratory failure. The study recommends the convalescent plasma therapy to potentially critical COVID-19 patients at their early phase of infection for better results
32348485
(J Infect Dis)
PMID
32348485
Date of Publishing: 2020 Jun 16
Title Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019
Author(s) nameZeng QL, Yu ZJ et al.
Journal J Infect Dis
Impact factor
4.73
Citation count: 78


60% of patients had side effects with Remdesivir treatment. Serious side events were also observed in 23% of patients. The most common adverse effects were diarrhea, rash, renal impairment, increased hepatic enzymes, and hypotension. Four patient had to discontinue the treatment, one because of preexisting renal failure, one because of multiple organ failure, and two because of elevated aminotransferases
32275812
(N Engl J Med)
PMID
32275812
Date of Publishing: 2020 Jun 11
Title Compassionate Use of Remdesivir for Patients with Severe Covid-19
Author(s) nameGrein J, Ohmagari N et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 776


A rapid increase in transaminases (aspartate aminotransferase and alanine aminotransferase) was observed after the introduction of HCQ. And a reduction in transaminases was observed after the drug was discontinued. HCQ have the potential for hepatotoxicity
32314698
(Am J Trop Med Hyg)
PMID
32314698
Date of Publishing: 2020 Jun
Title Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19
Author(s) nameFalcão MB, Pamplona de Góes Cavalcanti L et al.
Journal Am J Trop Med Hyg
Impact factor
2.25
Citation count: 5


2.4% of patients reported mild adverse effects when treated with HCQ and azithromycin. No serious adverse events were reported.
32387409
(Travel Med Infect Dis)
PMID
32387409
Date of Publishing: 2020 May-Jun
Title Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Author(s) nameMillion M, Lagier JC et al.
Journal Travel Med Infect Dis
Impact factor
3.42
Citation count: 132


Adverse effects in the lopinavir-ritonavir group were observed, 19 serious effects out of which 4 were serious gastrointestinal effects.
32187464
(N Engl J Med)
PMID
32187464
Date of Publishing: 2020 May 7
Title A Trial of LopinavirRitonavir in Adults Hospitalized with Severe Covid-19
Author(s) nameCao B, Wang Y et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 1546


Common adverse effects were observed in 48% of patients in the combination group (beta-1b, lopinavir-ritonavir, and ribavirin) and 49% of patients in the control group (lopinavir-ritonavir). One serious adverse effect was observed in the control group. The durations of the adverse events were same between the treatment groups. A patient in the control group had a serious adverse event of impaired hepatic enzymes.
32401715
(Lancet)
PMID
32401715
Date of Publishing: 2020 May 30
Title Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Author(s) nameHung IF, Lung KC et al.
Journal Lancet
Impact factor
43.38
Citation count: 352


Out of 155 patients in the Remdesivir group, 102 patients had adverse effects. Of 78 patients in the placebo group, 50 patients had adverse effects. 28 and 20 serious adverse effects were reported in the Remdesivir group and placebo group, respectively. 18 in the remdesivir group and four in the placebo group discontinued the study drug because of adverse events or serious adverse events.
32423584
(Lancet)
PMID
32423584
Date of Publishing: 2020 May 16
Title Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Author(s) nameWang Y, Zhang D et al.
Journal Lancet
Impact factor
43.38
Citation count: 738